Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Lisa K, Jennings"'
Autor:
Francesco Franchi, MD, Fabiana Rollini, MD, Victor Kairouz, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maaliki, MD, Latonya Been, AAS, Jason Piraino, DPM, Andres M. Pineda, MD, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M. Zenni, MD, Lisa K. Jennings, PhD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://doaj.org/article/b7ea15f9ac70419180a5ce0ec8e4c853
Autor:
Francesco Franchi, Fabiana Rollini, Gabriel Faz, Jose Ramon Rivas, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Mustafa Wali, Ahmed Nawaz, Gabriel Silva, Zubair Shaikh, Naji Maaliki, Kerolos Fahmi, Latonya Been, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Usman Baber, Roxana Mehran, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. Th
Externí odkaz:
https://doaj.org/article/febf58ad375f48bcb33144fe435a90c7
Autor:
Oliver Borst, Patrick Münzer, Nada Alnaggar, Sascha Geue, Roland Tegtmeyer, Dominik Rath, Michal Droppa, Peter Seizer, Stefan Heitmeier, Johan W.M. Heemskerk, Lisa K. Jennings, Robert F. Storey, Dominick J. Angiolillo, Bianca Rocca, Henri Spronk, Hugo Ten Cate, Meinrad Gawaz, Tobias Geisler
Publikováno v:
Blood Advances, Vol 2, Iss 6, Pp 715-730 (2018)
Abstract: Very low–dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary syndrome (ACS) with a tolerable bleeding risk profile. To
Externí odkaz:
https://doaj.org/article/d9e3884a70ea426791e0641813794a24
Autor:
Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda Maldonado, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick Angiolillo
Publikováno v:
Thrombosis and Haemostasis.
Background:To date, there is no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen. Objectives: To assess the feasibility of switching from DAPT to DPI and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::538f150e1e47420b9595f99e0422a6b2
https://doi.org/10.1055/a-2098-6639
https://doi.org/10.1055/a-2098-6639
Autor:
C. Michael Gibson, Lisa K. Jennings, Gerald Chi, Megan K. Yee, Rim Halaby, Tarek Nafee, Fahad AlKhalfan, Mathieu Kerneis, Serge Korjian, Yazan Daaboul, Samuel Z. Goldhaber, Russel D. Hull, Adrian F. Hernandez, Alexander T. Cohen, Robert A. Harrington
Publikováno v:
TH Open, Vol 02, Iss 01, Pp e16-e24 (2018)
Abstract Background Elevated D-dimer concentrations are associated with an increased risk of venous thromboembolism (VTE). However, they may also provide prognostic value. The present analysis sought to study the association of D-dimer levels with
Externí odkaz:
https://doaj.org/article/33e88693210b47f98f116256d18db492
Autor:
Salvatore Giordano, Luis Ortega-paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick J. Angiolillo
Publikováno v:
European Heart Journal Supplements. 24
Aims To assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and to compare the pharmacodynamic (PD) profiles of these treatment regimens. Methods and results This was a prospective, randomized, P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8473e5fdb5ba45c362300bd9a82fea0
https://doi.org/10.1093/eurheartjsupp/suac121.768
https://doi.org/10.1093/eurheartjsupp/suac121.768
Autor:
Deepak L. Bhatt, Charles V. Pollack, C. David Mazer, Dominick J. Angiolillo, Ph. Gabriel Steg, Stefan K. James, Jeffrey I. Weitz, Rohit Ramnath, Susan E. Arnold, Michael C. Mays, Bret R. Umstead, Barbara White, Lisa L. Hickey, Lisa K. Jennings, Benjamin J. Curry, John S. Lee, Subodh Verma
Publikováno v:
NEJM Evidence. 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7484c3f9f26b889fd1f76bafd3e98386
https://doi.org/10.1056/evidoa2100047
https://doi.org/10.1056/evidoa2100047
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Tobias Geisler, Lisa K Jennings, Theodore A Bass, Dominick J Angiolillo
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 8(7)
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most studies the antiplatelet agent of choice used in adjunct to a vascular dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd7f29531b194772f31f99affe35102
https://pubmed.ncbi.nlm.nih.gov/35353154
https://pubmed.ncbi.nlm.nih.gov/35353154
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Tobias Geisler, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Thrombosis and haemostasis. 122(8)
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI), reduces atherothrombotic events in patients with stable atherosclerotic disease.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e8db2c8371a8f8f2057ff6b192adfa
https://pubmed.ncbi.nlm.nih.gov/34983074
https://pubmed.ncbi.nlm.nih.gov/34983074
Autor:
Malhar Agarwal, Naji Maaliki, Fabiana Rollini, Theodore A. Bass, Jose Rivas Rios, Siva Suryadevara, Gabriel Silva, Andres M. Pineda, Daniel Soffer, Lisa K. Jennings, Maryuri Briceno, Victor Kairouz, Andrea Rivas, Mustafa Wali, Francesco Franchi, Ahmed Nawaz, Dominick J. Angiolillo, Jason A. Piraino, Zubair Shaikh, Latonya Been, Martin M. Zenni
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::761721f8088e6e0941192b82cd4d54b2
https://doi.org/10.1016/j.jacbts.2019.07.011
https://doi.org/10.1016/j.jacbts.2019.07.011